Gynecologic Oncology

ESMO 2025

Questions discussed in this category

What are your top takeaways in Gyn Cancers from ESMO 2025?

1 Answer available

Papers discussed in this category

N Engl J Med, 2022 Jan 19

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

Lancet (London, England), 2025 Jun 02

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.

Journal of gynecologic oncology, 2025 Jul

Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.

The Lancet. Oncology, 2022 Jun 09

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.

Related Topics in Gynecologic Oncology